Frontline Management of Atopic Dermatitis in Adults - Episode 8
A Primary Care Perspective on Newer-Generation Systemic Therapies
Panelists discuss how primary care awareness of biologics and Janus kinase (JAK) inhibitors for atopic dermatitis (AD) remain limited, with outreach efforts by dermatology groups and industry partners showing mixed success in education. While patients on biologics generally report significant symptom improvement, measured through validated tools like EASI, SCORAD, and patient-reported outcome measures, ongoing efforts are needed to bridge the knowledge gap in primary care settings.
Video content above in prompted by the following:
- How would you characterize awareness of systemic treatments like biologics and JAK inhibitors for the treatment of AD among primary care practitioners?
- Are the dermatology community/industry/primary care partners /educational meetings reaching primary care providers?
- Do patients using biologics typically report satisfactory improvement in symptoms?
- How do you quantify/assess such improvements?
